Coherus Oncology, Inc. (CHRS) Return on equity 2016–2025
Coherus Oncology, Inc. (CHRS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
275.4%FY2025 · since FY2016: -620.3% → 275.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 275.4% | — |
| FY2021 | -293.8% | -340.8 pp |
| FY2020 | 47.1% | -38.3 pp |
| FY2019 | 85.4% | — |
| FY2017 | -780.0% | -159.7 pp |
| FY2016 | -620.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice